EPS Bio Technology

EPS Bio Technology Receivables

The Accounts Receivable of EPS Bio Technology (4183.TWO) as of Nov 9, 2026 is 149.80 M TWD. In the previous year, Accounts Receivable was 92.09 M TWD — a change of 62.67% (higher).

Receivables

149.80 MTWD

YoY

62.67%

Last updated:

Accounts Receivable of EPS Bio Technology is 2024 149.80 M TWD. Accounts Receivable of EPS Bio Technology was 2023 92.09 M TWD. It decreases by 62.67% higher compared to the previous year.

The EPS Bio Technology Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
59.85 M TWD
Jan 1, 2018
73.87 M TWD
Jan 1, 2019
105.95 M TWD
Jan 1, 2020
80.47 M TWD
Jan 1, 2021
101.23 M TWD
Jan 1, 2022
78.81 M TWD
Jan 1, 2023
92.09 M TWD
Jan 1, 2024
149.80 M TWD
The EPS Bio Technology Receivables history
YEARReceivablesYoY
149.80 MTWD+62.67%
92.09 MTWD+16.85%
78.81 MTWD-22.15%
101.23 MTWD+25.80%
80.47 MTWD-24.05%
105.95 MTWD+43.42%
73.87 MTWD+23.43%
59.85 MTWD-49.10%
117.58 MTWD+59.50%
73.72 MTWD+27.46%
57.84 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EPS Bio Technology Stock analysis

What does EPS Bio Technology do? EPS Bio Technology Corp, listed on the Taiwan Stock Exchange with ticker 4183.TWO and ISIN TW0004183009, is headquartered in Baoshan, Taiwan. The company operates within the Health Care sector, specifically in the Health Care industry. It has a workforce of 123 employees. EPS Bio Technology Corp completed its initial public offering (IPO) on November 13, 2012. The company's primary business activities involve the development and manufacture of blood glucose monitoring systems, as well as the development and sales of various medical and related medical equipment. Its main product lines include blood glucose testers, blood glucose test strips, and electric breast pumps. The firm primarily distributes its products to international markets, with a focus on Europe, North America, and other regions in Asia. The company's official website is http://www.epsbio.com.tw/. EPS Bio Technology Corp does not disclose specific financial figures or additional details about its operations beyond the provided information. The company is based in Baoshan, Hsinchu, though the source description mentions Hsinchu as the headquarters location, which is consistent with the city provided in the data. The company's operations are centered around medical technology, with an emphasis on diagnostic and consumer health products. EPS Bio Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EPS Bio Technology stock

Accounts Receivable of EPS Bio Technology is 149.80 M TWD in 2024.

Accounts Receivable of EPS Bio Technology changed from 92.09 M TWD to 149.80 M TWD, representing a 62.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable EPS Bio Technology since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's EPS Bio Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — EPS Bio Technology

All Key Metrics — EPS Bio Technology